Impressive results from phase 3 RESONATE trial in CLL
Combining ublituximab with the novel PI3K inhibitor TGR-1202 for CLL
Treating CLL with venetoclax
What are the practical considerations for monoclonal antibody infusion?
HARMONY and CLL: the future of research and databases